tert-butyl {4-[3-(4-amino-phenyl)-2-(tert-butoxycarbonylmethyl-amino)-propyl]-7-tert-butoxycarbonylmethyl-[1,4,7]triazonan-1-yl}-acetate | 1016237-83-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl {4-[3-(4-amino-phenyl)-2-(tert-butoxycarbonylmethyl-amino)-propyl]-7-tert-butoxycarbonylmethyl-[1,4,7]triazonan-1-yl}-acetate
• 英文别名: Tert-butyl 2-[[1-(4-aminophenyl)-3-[4,7-bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-1,4,7-triazonan-1-yl]propan-2-yl]amino]acetate
• CAS: 1016237-83-4
• 化学式: C₃₃H₅₇N₅O₆
• 分子量: 619.845
• InChiKey: OXGMHYRQZLYVHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  44
• 可旋转键数：
  17
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  tert-butyl {4-[3-(4-amino-phenyl)-2-(tert-butoxycarbonylmethyl-amino)-propyl]-7-tert-butoxycarbonylmethyl-[1,4,7]triazonan-1-yl}-acetate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 以97%的产率得到{4-[3-(4-amino-phenyl)-2-(carboxymethyl-amino)-propyl]-7-carboxymethyl-[1,4,7]triazonan-1-yl}-acetic acid
  参考文献：
  名称：

  Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using

  摘要：

  用带有氨基或羟基的1,4,7-三氮杂环壬烷-N,N′,N″-三乙酸和1,4,7,10-四氮杂环十二烷-N,N′,N″,N′″-四乙酸化合物替代，以及它们的金属配合物、组合物、制备方法以及在诊断成像和治疗细胞疾病中的应用。

  公开号：

  US09115094B2
• 作为产物：
  描述：

  tert-butyl (1-(4-nitrophenyl)-3-oxopropan-2-yl)carbamate 在 palladium 10% on activated carbon 、 氢气 、 N,N-二异丙基乙胺 、 三氟乙酸 、 potassium iodide 作用下， 以 甲醇 、 氯仿 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 50.0 ℃ 、137.9 kPa 条件下， 反应 55.63h， 生成 tert-butyl {4-[3-(4-amino-phenyl)-2-(tert-butoxycarbonylmethyl-amino)-propyl]-7-tert-butoxycarbonylmethyl-[1,4,7]triazonan-1-yl}-acetate
  参考文献：
  名称：

  Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using

  摘要：

  用带有氨基或羟基的1,4,7-三氮杂环壬烷-N,N′,N″-三乙酸和1,4,7,10-四氮杂环十二烷-N,N′,N″,N′″-四乙酸化合物替代，以及它们的金属配合物、组合物、制备方法以及在诊断成像和治疗细胞疾病中的应用。

  公开号：

  US09115094B2

文献信息

• Bile acid-based polyaminocarboxylate conjugates as targeted antitumor agents
  作者：Hyun-Soon Chong、Hyun A. Song、Xiang Ma、Sooyoun Lim、Xiang Sun、Santosh B. Mhaske

  DOI：10.1039/b823000e

  日期：——

  Bile acid–polyaminocarboxylate conjugates containing NE3TA, a potential iron chelator displayed significant cytotoxicities in both HeLa and HT29 colon cancer cells, and cholic acid–NE3TA attached to an organic fluorophore was shown to enter the HT29 cancer cells.

  含有 NE3TA（一种潜在的铁螯合剂）的胆汁酸-多胺羧酸共轭物在 HeLa 和 HT29 结肠癌细胞中都显示出显著的细胞毒性，而附着有机荧光团的胆酸-NE3TA 被证明能进入 HT29 癌细胞。
• Synthesis and Evaluation of Novel Polyaminocarboxylate-Based Antitumor Agents
  作者：Hyun-Soon Chong、Xiang Ma、Haisung Lee、Phuong Bui、Hyun A. Song、Noah Birch

  DOI：10.1021/jm701307j

  日期：2008.4.1

  Iron depletion, using iron chelators targeting transferrin receptor (TfR) and ribonucleotide reductase (RR), is proven to be effective in the treatment of cancer. We synthesized and evaluated novel polyarninocarboxylate-based chelators NETA, NE3TA, and NE3TA-Bn and their bifunctional versions C-NETA, C-NE3TA, and N-NE3TA for use in iron depletion tumor therapy. The cytotoxic activities of the novel polyaminocarboxylates were evaluated in the HeLa and HT29 colon cancer cell lines and compared to the clinically available iron depletion agent DFO and the frequently explored polyaminocarboxylate DTPA. All new chelators except C-NETA displayed enhanced cytotoxicities in both HeLa and HT29 cancer cells compared to DFO and DTPA. Incorporation of the nitro functional unit for conjugation to a targeting moiety into the two potent non-functionalized chelators NE3TA and NE3TA-Bn (C-NE3TA and N-NE3TA) was well-tolerated and resulted in a minimal decrease in cytotoxicity. Cellular uptake of C-NE3TA, examined using a confocal microscope, indicates that the chelator is taken up into HT29 cancer cells.
• A novel cholic acid-based contrast enhancement agent for targeted MRI
  作者：Hyun-Soon Chong、Hyun A. Song、Sooyoun Lim、Keith Macrenaris、Xiang Ma、Haisung Lee、Phuong Bui、Thomas Meade

  DOI：10.1016/j.bmcl.2008.01.044

  日期：2008.4

  The novel Gd(III) complexes of heptadentate ligands NE3TA and NE3TA-Bn were prepared, and their relaxivities were measured and favorably compared to the commercially available MRI contrast enhancement agent Gd(DOTA). NE3TA was conjugated with cholic acid (CA) to produce CA-NE3TA. TEM images of Gd(CA-NE3TA) indicate that the complex self-assembles forming nano-sized micelles and displays an over threefold increased relaxivity compared to Gd(DOTA). The new cholic acid-conjugated nanoparticle MR contrast enhancement agent, Gd(CA-NE3TA) possesses great promise for use in targeted MRI. (C) 2008 Published by Elsevier Ltd.
• US9115094B2
  申请人：——

  公开号：US9115094B2

  公开（公告）日：2015-08-25